(Q38963613)

English

Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia

scientific article published on 16 September 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

0 references

author name string

W Zeijlemaker

1

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

A Kelder

2

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Y J M Oussoren-Brockhoff

3

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

W J Scholten

4

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

A N Snel

5

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

D Veldhuizen

6

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

J Cloos

7

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

G J Ossenkoppele

8

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

G J Schuurhuis

9

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

publication date

16 September 2015

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

708-715

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

https://scigraph.springernature.com/pub.10.1038/leu.2015.255

0 references

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.255

21 January 2018

Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.255

21 January 2018

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.255

21 January 2018

The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.255

21 January 2018

Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.255

21 January 2018

Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.255

21 January 2018

Monitoring minimal residual disease in peripheral blood in B-lineage acute lymphoblastic leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.255

21 January 2018

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.255

21 January 2018

Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.255

21 January 2018

Basic principles of ROC analysis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.255

21 January 2018

Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.255

21 January 2018

Minimal residual disease in acute myeloid leukemia: already predicting a safe haven?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.255

21 January 2018

Quantification of CBFB-MYH11 fusion gene levels in paired peripheral blood and bone marrow samples by real-time PCR.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.255

21 January 2018

Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.255

21 January 2018

Minimal residual core binding factor AMLs by real time quantitative PCR--initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.255

21 January 2018

Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.255

21 January 2018

Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.255

21 January 2018

Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.255

21 January 2018

Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.255

21 January 2018

Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.255

21 January 2018

Slow relapse in acute myeloid leukemia with inv(16) or t(16;16).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.255

21 January 2018

Monitoring of minimal residual disease in patients with MLL-AF6-positive acute myeloid leukaemia by reverse transcriptase polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.255

21 January 2018

Quantitation of minimal residual disease in t(8;21)-positive acute myelogenous leukemia patients using real-time quantitative RT-PCR

1 reference

https://pubmed.ncbi.nlm.nih.gov/26373238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/26373238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/26373238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monitoring of minimal residual disease in acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/26373238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell compartment offers additional prognostic information in acute myeloid leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/26373238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse

1 reference

https://pubmed.ncbi.nlm.nih.gov/26373238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/26373238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/26373238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/26373238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine

1 reference

https://pubmed.ncbi.nlm.nih.gov/26373238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts

1 reference

https://pubmed.ncbi.nlm.nih.gov/26373238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Extramedullary disease in patients with acute myeloid leukemia assessed by 18F-FDG PET

1 reference

https://pubmed.ncbi.nlm.nih.gov/26373238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Minimal residual disease monitoring by flow cytometry

1 reference

https://pubmed.ncbi.nlm.nih.gov/26373238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol

1 reference

https://pubmed.ncbi.nlm.nih.gov/26373238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Minimal residual disease in acute myeloid leukemia: coming of age.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26373238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL

1 reference

https://pubmed.ncbi.nlm.nih.gov/26373238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse

1 reference

https://pubmed.ncbi.nlm.nih.gov/26373238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26373238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow

1 reference

https://pubmed.ncbi.nlm.nih.gov/26373238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/LEU.2015.255

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38963613&oldid=1799685085"